Union Health Minister Shri J P Nadda reviewed the progress and initiatives of the Indian Pharmacopoeia Commission (IPC) at a meeting held in New Delhi, with senior officials including Ms. Nivedita Shukla Verma, Secretary of the Department of Chemicals and Petro‑Chemicals and additional charge as Secretary of the Ministry of Health and Family Welfare in attendance. The review covered IPC’s role in strengthening drug standards and pharmacovigilance, contributing to national public health objectives and regulatory excellence.
During the meeting, Nadda acknowledged IPC’s sustained efforts in enhancing pharmacopoeial standards and pharmacovigilance activities, which align with the government’s vision of Atmanirbhar Bharat and Viksit Bharat by promoting self‑reliance, scientific excellence and robust healthcare quality benchmarks. He highlighted IPC’s pivotal role in ensuring the quality, safety and efficacy of medicines, reinforcing it as a critical scientific and regulatory reference that ensures uniform medicine standards across India.
The review noted that the Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities and strengthening the country’s standing as a major contributor to global pharmacopeial standards.
Officials also discussed plans for the upcoming 10th edition of the Indian Pharmacopoeia 2026, which is scheduled to be launched by the Union Health Minister in the first week of January 2026.
The meeting emphasised IPC’s crucial role in implementing the Pharmacovigilance Programme of India (PvPI) to monitor adverse drug reactions and enhance patient safety, along with efforts to improve reporting systems and build capacity among healthcare professionals. In addition, Nadda encouraged continued focus on innovation, digitalisation and global harmonisation of standards to support broader access to safe and quality medicines, in line with national and international health goals.
Details of IPC’s activities were presented by Dr V. Kalaiselvan, Secretary‑cum‑Scientific Director of the Commission, who reaffirmed the commitment to further strengthen pharmacopoeial and pharmacovigilance standards while enhancing international collaboration and contributing to both national and global health objectives.
Also present at the meeting was Shri Harsh Mangla, Joint Secretary of the Ministry of Health and Family Welfare, along with other senior ministry officials, underlining the government’s continued emphasis on drug quality, regulatory oversight and public health protection.
